Skip to main content
SpringerLink
Log in

Properties of sustained-release single-dose formulations for vulvovaginal candidiasis

The example of butoconazole vaginal emulsion as a drug-sparing formulation

  • Healthcare Technology Review
  • Published:
American Journal of Drug Delivery

Abstract

Vaginally applied imidazoles are the first-line treatment of vulvovaginal candidiasis (VVC). The need to develop a less messy and more patient acceptable treatment regimen led to the development of a treatment schedule from the original 3 weeks to 7 days and, then, to 3 days. Finally, it was attempted to design a single-dose treatment regimen. Currently in the US, three single-dose vaginal preparations are available: 2% butoconazole sustained release (SR) [100mg butoconazole; Gynazole-1®], 6.5% tioconazole (300mg tioconazole; Vagistat-1®), and 2% miconazole vaginal ovule (Monistat1®, combination pack providing an ovule of 1200mg of miconazole and 2% monistat cream for external use). Clotrimazole 500mg single-dose vaginal tablet was used earlier and has been withdrawn from the market.

In clinical studies, treatment success is measured by the regression of signs and symptoms of VVC (clinical cure) and by the negative mycological cultures (microbiological cure). 2% butoconazole SR has been formulated in an emulsion that adheres to wet surfaces of vaginal mucosa infected with Candida albicans. After the single dose, butoconazole is gradually released from the emulsion in a sustained release fashion for 3–6 days and acts on the fungus. The results of treatment with 2% butoconazole SR were equivalent to a 7-day schedule with 2% miconazole. Adverse effects have been infrequent and usually mild. 2% butoconazole in the SR bioadhesive formulation is drug-sparing compared with treatment regimens providing a total of 300–700mg of imidazoles in 3–7 days.

The second single-dose preparation, 6.5% tioconazole, for VVC provides tioconazole 300mg in a vaginal ointment. This compound has been compared with 2% miconazole in a separate and independent set of clinical trials; 2% miconazole was superior to 6.5% tioconazole in the microbiological cure rates at the first follow-up examination.

The success of a single-dose antifungal treatment also depends upon the vehicle used to deliver the active drug to the target tissue. In case of 2% butoconazole SR the vehicle is formulated as a hydrophilic emulsion that adheres to the surface of the moist vaginal mucosa for 3–6 days.

Representative of the orally active preparations is a single dose of fluconazole 150mg. The efficacy results of oral fluconazole are similar to the 7-day vaginal antifungal preparations; however, there is the possibility of the development of resistance and systemic adverse effects affecting the liver and kidneys.

The sustained-release technology used for single dose of 2% butoconazole is an innovative approach to vaginal drug delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III
Table IV
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol 1992; 32: 248–55

    PubMed  CAS  Google Scholar 

  2. Sobel JD, Vasquez J, Lynch M, et al. Vaginitis due to Sacchromyces cerevisiae: epidemiology, clinical aspects and therapy. Clin Infect Dis 1993; 16: 93–9

    Article  PubMed  CAS  Google Scholar 

  3. Redondo-Lopez V, Lynch M, Schmitt C, et al. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol 1990; 76: 651–5

    PubMed  CAS  Google Scholar 

  4. Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic yeast vaginal isolates. J Med Vet Mycol 1994; 32: 267–74

    Article  PubMed  CAS  Google Scholar 

  5. Brown D, Henzl MR, Kaufman RH, et al. Butoconazole nitrate 2% for vulvovaginal candidiasis: new, single-dose vaginal cream formulation vs seven-day treatment with miconazole nitrate. J Reprod Med 1999; 44: 933–8

    PubMed  CAS  Google Scholar 

  6. Matthews T. Butoconazole: pharmacologic considerations, chemistry, and microbiology. J Reprod Med 1986; 31 Suppl. 7: 655–7

    Google Scholar 

  7. Henzl MR. Vulvovaginal candidiasis: historical perspectives and current trends. J Reprod Med 1986; 31 Suppl. 7: 641–4

    Google Scholar 

  8. Brown D, Henzl M, LePage ME, et al. Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis: comparison with miconazole nitrate and placebo. J Reprod Med 1986; 31: 1045–8

    PubMed  Google Scholar 

  9. Adamson GD, Brown D, Standard JV, et al. Three-day treatment with butoconazole vaginal suppositories for vulvovaginal candidiasis. J Reprod Med 1986; 31: 131–2

    PubMed  CAS  Google Scholar 

  10. Drugs approved by the FDA. Drug Name: Femstat 3 (butoconazole nitrate 2%). Available from URL: http://www.centerwatch.com/patient/drugs/dru27.html [Accessed 2004 Aug 25]

  11. Thompson DJ, Levinson S. A bioadhesive topical drug delivery system. Drug Deliv Syst Sci 2002; 2: 17–9

    Google Scholar 

  12. Levinson S, Thompson DJ. VagiSite bioadhesive technology. In: Rathbone MJ, Hadgraft J, Roberts MS, editor. Modified-release drug delivery technology. New York: Marcel Dekker Inc, 2002: 801–806

    Chapter  Google Scholar 

  13. Weinstein L, Henzl MR, Tsina IW. Vaginal retention of 2% butoconazole nitrate cream; comparison of a standard and sustained release preparation. Clin Ther 1994; 16: 930–4

    PubMed  CAS  Google Scholar 

  14. Dickerson JK, Christian CD, Chu N, et al. Vaginal absorption of (3H)-butoconazole nitrate in women with vulvovaginal candidiasis: importance of technique. Poster session. Associates of Clinical Pharmacology meeting; 1987 Dec 1–4; Vail (CO). J Clinical Res Drug Dev. 1994

  15. Henzl MR. Metabolism of butoconazole. J Reprod Med 1986; 31/7 Suppl. 7: 658–9

    Google Scholar 

  16. Droegemuller W, Adamson D, Brown D, et al. Three-day treatment with butoconazole nitrate for vulvovaginal candidiasis. Obstet Gynecol 1984; 64: 530–4

    Google Scholar 

  17. Faro S, Henzl MR, Shulman L, et al. Treating vulvovaginal candidiasis: three studies reviewed. Female Patient 2001; March Suppl.: 26–31

    Google Scholar 

  18. Jevons S, Gymer GE, Brammer KW, et al. Antifungal activity of tioconazole (UK 20,349), a new imidazole derivative. Antimicrob Agents Chemother 1979; 15: 597–602

    Article  PubMed  CAS  Google Scholar 

  19. Stein GE, Gurwith D, Munnaw N, et al. Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis. Antimicrob Agents Ther 1986; 29: 969–71

    Article  CAS  Google Scholar 

  20. Schaetzing A. Tioconazole in the treatment of vaginal candidosis. Mycoses 1988; 31: 584–9

    Article  PubMed  CAS  Google Scholar 

  21. Clissold SP, Heel RC. Tioconazole: a review. Drugs 1986; 31: 29–51

    Article  PubMed  CAS  Google Scholar 

  22. Marriott MS, Brammer KW, Faccini J, et al. Tioconazole, a new broad spectrum antifungal agent: preclinical studies related to vaginal candidiasis. Gynakol Rundsch 1983; 23 Suppl. 1: 1–11

    Article  Google Scholar 

  23. Berg D, Buchel KH, Plempel M, et al. Antimycotic sterol biosynthesis inhibitors. TIPS 1986 Jun, 238

    Google Scholar 

  24. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263–72

    Article  PubMed  CAS  Google Scholar 

  25. Upmanlis DH, Cone TL, Lamia CA, et al. Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100mg cream for 7 days. J Womens Health Gend Based Med 2000; 9: 421–9

    Article  Google Scholar 

  26. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351: 876–83

    Article  PubMed  CAS  Google Scholar 

  27. Edelman DA, Grant S. One-day therapy for vaginal candidiasis: a review. J Reprod Med 1999; 44: 543–7

    PubMed  CAS  Google Scholar 

  28. Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at risk HIV-seronegative women. J Infect Dis 2001; 183: 286–93

    Article  PubMed  CAS  Google Scholar 

  29. Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34–8

    Article  PubMed  CAS  Google Scholar 

  30. Cross EW, Park S, Perlin DS. Cross-resistance of clinical isolates of Candia albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 2000; 6: 155–61

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The studies discussed in this review were conducted as a joint research project between the KV Pharmaceutical Company and Syntex Research. As Project Team Leader for vaginal antifungal compounds, the author directed the clinical part of the development process (about 40 clinical trials) under his regular work assignment. There was no special financial compensation associated with the studies.

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Stanford University School of Medicine, Stanford, California, USA

    Milan R. Henzl

Authors
  1. Milan R. Henzl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henzl, M.R. Properties of sustained-release single-dose formulations for vulvovaginal candidiasis. Am J Drug Deliv 3, 227–237 (2005). https://doi.org/10.2165/00137696-200503040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00137696-200503040-00003

Keywords

Search

Navigation